Alnylam Pharmaceuticals (ALNY) vs. IONS and ARWR: Can Pipeline Growth Restore Confidence After the Guidance Cut?

What happened: A bullish Substack thesis on Alnylam Pharmaceuticals (ALNY) was published September 11 at $248.68 per share. The stock has since fallen 8.70%, with the decline tied to concerns about slower AMVUTTRA demand growth after an earlier sales outlook reduction and uncertainty ahead of pipeline data. Key Why it matters: The content frames the stock as trading at a premium to peers, roughly 41.1 times trailing and 28.1 times forward earnings versus a peer average of about 18 times trailing and 16.2 times forward, reflecting a bet that new product launches can sustain earnings growth.

A bullish Substack thesis on Alnylam Pharmaceuticals (ALNY) was published September 11 at $248.68 per share. The stock has since fallen 8.70%, with the decline tied to concerns about slower AMVUTTRA demand growth after an earlier sales outlook reduction and uncertainty ahead of pipeline data. Key

The content frames the stock as trading at a premium to peers, roughly 41.1 times trailing and 28.1 times forward earnings versus a peer average of about 18 times trailing and 16.2 times forward, reflecting a bet that new product launches can sustain earnings growth.